1-[3-(3-chlorophenyl)propyl]-3-(2-hydroxy-2,2-diphenylacetoxy)-1-azoniabicyclo[2.2.2]octane bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[3-(3-chlorophenyl)propyl]-3-(2-hydroxy-2,2-diphenylacetoxy)-1-azoniabicyclo[2.2.2]octane bromide
• 化学式: C30H33BrClNO3
• 分子量: 570.9
• InChiKey: DTPNUAXJFJVFER-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(3-氯苯基)-1-丙醇 在 四溴化碳 、 三苯基膦 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 66.0h， 生成 1-[3-(3-chlorophenyl)propyl]-3-(2-hydroxy-2,2-diphenylacetoxy)-1-azoniabicyclo[2.2.2]octane bromide
  参考文献：
  名称：

  Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

  摘要：

  The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(-)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[ 2.2.2] octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM(3)R). Compared to 1 and 5, (R)-(-)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(-)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(-)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

  DOI：

  10.1016/j.bmc.2019.06.016

文献信息

• Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity
  作者：Yasunobu Yamashita、Ken-ichiro Tanaka、Naoki Yamakawa、Teita Asano、Yuki Kanda、Ayaka Takafuji、Masahiro Kawahara、Mitsuko Takenaga、Yoshifumi Fukunishi、Tohru Mizushima

  DOI：10.1016/j.bmc.2019.06.016

  日期：2019.8

  The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(-)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[ 2.2.2] octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM(3)R). Compared to 1 and 5, (R)-(-)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(-)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(-)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.